p.86 抽出テキスト

157. Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail 2023;25:1891–8. https://doi.org/ 10.1002/ejhf.3036 158. Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting. Circulation 2025;151:976–89. https://doi.org/10.1161/ CIRCULATIONAHA.124.072156 159. Kozhuharov N, Martin J, Wussler D, Lopez-Ayala P, Belkin M, Strebel I, et al. Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. Eur J Heart Fail 2022; 24:1545–54. https://doi.org/10.1002/ejhf.2618 160. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151:999–1005. https://doi.org/10. 1016/j.ahj.2005.10.011 161. Lu Y, Chen J, Chen R, Lukwaro AF, Zhou S, Luo Y, et al. Determining kidney function-specific thresholds for N-terminal pro-B-type natriuretic peptide in heart failure risk prediction among patients with chronic kidney disease: a multicentre, observational, cohort study. Heart 2025;111:828–34. https:// doi.org/10.1136/heartjnl-2024-324679 162. Neuen BL, Vaduganathan M, Claggett BL, Beldhuis I, Myhre P, Desai AS, et al. Natriuretic peptides, kidney function, and clinical outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 2025;13:28–39. https:// doi.org/10.1016/j.jchf.2024.08.009 163. Taylor CJ, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, Jones NR, Roalfe AK, et al. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004–2018. Heart 2022;108:543–9. https://doi.org/10.1136/heartjnl-2021-319196 164. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105:S117–314. https://doi.org/ 10.1016/j.kint.2023.10.018 165. Katz DH, Burns JA, Aguilar FG, Beussink L, Shah SJ. Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction. JACC Heart Fail 2014;2:586–96. https://doi.org/10.1016/j.jchf.2014. 05.016 166. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009;374:543–50. https://doi.org/10.1016/S0140- 6736(09)61378-7 167. Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O’Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail 2018;11:e005288. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005288 168. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514–25. https://doi.org/10.1016/ S2213-8587(15)00040-6 169. Chen H, Chhor M, Rayner BS, McGrath K, McClements L. Evaluation of the diagnostic accuracy of current biomarkers in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Arch Cardiovasc Dis 2021;114:793–804. https://doi.org/10.1016/j.acvd.2021.10.007 170. Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, et al. An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score. Nat Med 2024;30:2258–64. https://doi. org/10.1038/s41591-024-03140-1 171. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391–412. https://doi.org/10.1002/ejhf.1741 172. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018;138:861–70. https://doi.org/10. 1161/CIRCULATIONAHA.118.034646 173. Selvaraj S, Myhre PL, Vaduganathan M, Claggett BL, Matsushita K, Kitzman DW, et al. Application of diagnostic algorithms for heart failure with preserved ejection fraction to the community. JACC Heart Fail 2020;8: 640–53. https://doi.org/10.1016/j.jchf.2020.03.013 174. Reddy YNV, Kaye DM, Handoko ML, van de Bovenkamp AA, Tedford RJ, Keck C, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol 2022;7:891–9. https://doi.org/10.1001/jamacardio.2022.1916 175. Li S, Zhu X, Zhang Y, Li F, Guo S. Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta-analysis. ESC Heart Fail 2023;10:2225–35. https://doi.org/10.1002/ehf2.14421 176. Guazzi M, Wilhelm M, Halle M, Van Craenenbroeck E, Kemps H, de Boer RA, et al. Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy—a clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Heart Fail 2022;24:1327–45. https://doi.org/10.1002/ejhf.2601 177. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077–84. https://doi.org/ 10.1056/NEJM200004133421502 178. Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, Ryan M, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med 2022;387:1351–60. https://doi.org/10.1056/ NEJMoa2206606 179. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607–16. https://doi.org/10.1056/NEJMoa1100356 180. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med 2016;374:1511–20. https://doi.org/10.1056/NEJMoa1602001 181. Shen Y, Yang Y. Comparing the diagnostic performance of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting cardiac sarcoidosis: a meta-analysis. Clin Imaging 2024;113:110248. https://doi.org/10.1016/j.clinimag.2024. 110248 182. Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; a systematic review and meta-analysis. J Nucl Cardiol 2020;27:2103–15. https://doi.org/10.1007/s12350-018-01582-y 183. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Cardiol 2019;4:1007–18. https://doi. org/10.1001/jamacardio.2019.2952 184. Sun JP, Xu TY, Ni XD, Yang XS, Hu JL, Wang SC, et al. Echocardiographic strain in hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy. Echocardiography 2019;36:257–65. https://doi.org/10.1111/ echo.14222 185. Pagourelias ED, Mirea O, Duchenne J, Van Cleemput J, Delforge M, Bogaert J, et al. Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters. Circ Cardiovasc Imaging 2017;10:e005588. https://doi.org/10.1161/ CIRCIMAGING.116.005588 186. Alba AC, Gaztanaga J, Foroutan F, Thavendiranathan P, Merlo M, Alonso-Rodriguez D, et al. Prognostic value of late gadolinium enhancement for the prediction of cardiovascular outcomes in dilated cardiomyopathy: an international, multi-institutional study of the MINICOR group. Circ Cardiovasc Imaging 2020;13:e010105. https://doi.org/10.1161/ CIRCIMAGING.119.010105 187. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2020;13:69–80. https://doi.org/10.1016/j. jcmg.2019.03.026 188. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171–9. https://doi.org/10. 1053/euhj.2001.2822 189. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75. https://doi.org/10.1186/s12968-017-0389-8 190. Quarta G, Husain SI, Flett AS, Sado DM, Chao CY, Tome Esteban MT, et al. Arrhythmogenic right ventricular cardiomyopathy mimics: role of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2013;15:16. https://doi. org/10.1186/1532-429X-15-16 191. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:855–61. https://doi.org/10.1161/ CIRCULATIONAHA.104.507723 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026